Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1998
|
| gptkbp:ATCCode |
L01BC06
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to capecitabine |
| gptkbp:eliminationHalfLife |
0.75 hours
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:capecitabine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xeloda
|
| gptkbp:indication |
adjuvant colon cancer
metastatic breast cancer metastatic colorectal cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
antineoplastic agent
prodrug of 5-fluorouracil |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
nausea vomiting diarrhea fatigue |
| gptkbp:usedFor |
gptkb:cancer
colorectal cancer gastric cancer |
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|